Jw Life Science Corp (234080) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Jw Life Science Corp KRW 30,641, price KRW 11,030, upside +177.8%, quality 61 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions.
Show more
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.
Stock analysis
Jw Life Science Corp (234080) currently trades at 11,030 KRW, while our model-based Fair Value estimate is 30,641 KRW, implying the stock looks roughly 64.0% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of 31,405 KRW per share, and 23 of the 24 models we run sit above the 11,030 KRW price.
Bear case: the Asset-Based group reads lowest at 9,544 KRW, and 1 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 19,221 KRW (bear) to 39,833 KRW (bull), the price of 11,030 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Jw Life Science Corp reported revenue of 258B KRW in FY2025 versus 170B KRW in FY2021, a compound +11.0%/yr. Reported net income was 28.6B KRW in FY2025, compounding +22.0%/yr from FY2021.
Key figures
Market cap 171B KRW (≈ $127M) · P/S ratio 0.67 · Dividend yield 5.0% · Net margin 11.1% · Return on equity 11.9% · Return on assets (EBIT) 11.4% · Operating margin 14.8% · Revenue (TTM) 254B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 178%, 234080 screens cheaper than that median.
Fair Value models
Bear 19,221 KRWFair Value 30,641 KRWBull 39,833 KRW
Price 11,030 KRW · Upside +177.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.79/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Start year 2020 (pandemic). Over 10 years: +7.4% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+16.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.6%
Dividend (yield on the price)5.0%
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.18% → 13%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −3.1% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jw Life Science Corp Fair Value". https://www.fairvalue-calculator.com/stock/234080
Frequently asked questions
Is Jw Life Science Corp (234080) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of 30,641 KRW versus a price of 11,030 KRW, about +178% upside (undervalued).
What is the fair value of 234080?
Our model-based fair value for Jw Life Science Corp is 30,641 KRW (as of Oct 2, 2026), built from audited fundamentals. The current price: 11,030 KRW.
What is the quality score of 234080?
Jw Life Science Corp has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jw Life Science Corp (234080)?
Our model-based price target is the fair value of 30,641 KRW (as of Oct 2, 2026) from 24 valuation models. Cautious scenario 19,221 KRW, optimistic scenario 39,833 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jw Life Science Corp stock forecast for 2026?
Our models put fair value at 30,641 KRW, about +178% upside versus a price of 11,030 KRW (undervalued). Cautious scenario 19,221 KRW, optimistic scenario 39,833 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jw Life Science Corp (234080)?
Jw Life Science Corp reported trailing-twelve-month revenue of about 254B KRW (latest available figure, as of Oct 2, 2026).
Does Jw Life Science Corp pay a dividend?
Jw Life Science Corp currently shows a dividend yield of about 4.99% relative to its recent price (as of Oct 2, 2026).
What growth is priced into Jw Life Science Corp (234080)?
For today's price to be fair in a discounted-cash-flow model, Jw Life Science Corp would have to grow free cash flow by -1.1 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.0 % per year. As of Oct 2, 2026.
What discount rate (WACC) does the fair value of 234080 use?
Our models discount Jw Life Science Corp at 11.6 %: a base by market capitalisation (micro), damped by beta 0.24, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Jw Life Science Corp that is -1.1 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Jw Life Science Corp (234080) delivered so far?
Over the past 5 years revenue at Jw Life Science Corp grew +7.0 % a year. The price currently implies -1.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Jw Life Science Corp (234080) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Jw Life Science Corp (-1.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Jw Life Science Corp (234080)?
The free-cash-flow yield on the price is 15.87 %: that much free cash flow Jw Life Science Corp produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Jw Life Science Corp (234080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jw Life Science Corp it is 30,641 KRW per share (as of Oct 2, 2026), against a price of 11,030 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Jw Life Science Corp stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 234080 trades below its calculated fair value: price 11,030 KRW, fair value 30,641 KRW, a gap of about +178% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 234080?
No. The price is what the market pays today (11,030 KRW); the fair value is what the company's own numbers justify (30,641 KRW). For Jw Life Science Corp the two are 19,611 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jw Life Science Corp worth?
The market values Jw Life Science Corp at about 171B KRW (market capitalisation, as of Oct 2, 2026). Per share that is 11,030 KRW; our models calculate a fair value of 30,641 KRW per share.
What do the bullish and bearish scenarios say about 234080?
Our models span a range for Jw Life Science Corp: cautious scenario 19,221 KRW, base 30,641 KRW, optimistic 39,833 KRW per share (as of Oct 2, 2026, price 11,030 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Jw Life Science Corp (234080)?
Balance-sheet figures for Jw Life Science Corp (as of Oct 2, 2026): return on equity 11.9%, debt of 0.15 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is 234080 from its 52-week high?
Jw Life Science Corp trades at 11,030 KRW, about 26% below its 52-week high of 14,856 KRW and 3% above the low of 10,730 KRW (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of 30,641 KRW is for.
Which stocks are comparable to Jw Life Science Corp?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jw Life Science Corp stock attractive at the current price?
The data as of Oct 2, 2026: price 11,030 KRW, calculated fair value 30,641 KRW (+178%), Quality Score 61/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 234080 calculated?
We run Jw Life Science Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 30,641 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Jw Life Science Corp currently trades 64 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jw Life Science Corp (234080)?
The closing price on Oct 2, 2026 was 11,030 KRW. Our model-based fair value is 30,641 KRW, about +178% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jw Life Science Corp right now?
The price is below even our cautious bear case (19,221 KRW). The market is more pessimistic than our downside scenario. Solid quality (61/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (19,221 KRW to 39,833 KRW) leaves room in how you read the outcome.
Key figures of Jw Life Science Corp
How large is the market capitalisation of Jw Life Science Corp (234080)?
The market capitalisation of Jw Life Science Corp is 171B KRW (≈ $127M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jw Life Science Corp (234080)?
The price-to-sales ratio of Jw Life Science Corp is 0.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Jw Life Science Corp (234080)?
The dividend yield of Jw Life Science Corp is 5.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jw Life Science Corp (234080)?
The net margin of Jw Life Science Corp is 11.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jw Life Science Corp (234080)?
The return on equity (ROE) of Jw Life Science Corp is 11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jw Life Science Corp (234080)?
On an EBIT basis the return on assets of Jw Life Science Corp is 11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jw Life Science Corp (234080)?
The operating margin of Jw Life Science Corp is 14.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jw Life Science Corp (234080)?
Revenue at Jw Life Science Corp is growing +1.6% versus a year earlier (3y avg +10.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jw Life Science Corp (234080)?
Earnings per share at Jw Life Science Corp are growing −28.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Jw Life Science Corp (234080) carry?
The net debt of Jw Life Science Corp is 40.6B KRW (fiscal year 2025, ≈ 1.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jw Life Science Corp in the live analysis
One click puts Jw Life Science Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
